Regarding the fact that ASPSCR1 tumors were recently shown to harbor angiogenesis signature,27 we performed exploratory analysis to assess whether there are difference of response rate, PFS or OS in the 3 fusion transcript groups: TFEB (n = 6), other-TFE3 (n = 4), and ASPSCR1-TFE3 translocation RCC (n = 6). The gene discussed is TFE3; the disease is renal cell carcinoma.